Gurgaon (Haryana), India, August 07, 2024: In today’s rapidly evolving digital domain, efficiently managing software assets and infrastructure is crucial for business success. Enter Forescribe, the pioneering SaaS platform established in 2023, which is redefining digital infrastructure management for mid-size and large enterprises worldwide.
Under the guidance of Vinayak Gupta, a veteran with a decade’s worth of experience across Product, Marketing, Presales, Engineering, and Solution Consulting in both MNCs and startups, Forescribe has carved a niche in optimising operational inefficiencies. Vinayak’s deep understanding of technological trends and business dynamics has driven Forescribe to develop a platform that not only enhances visibility and control over software assets but also dramatically reduces operational costs.
Forescribe leverages cutting-edge artificial intelligence to empower organisations. The platform’s AI-driven analytics and predictive insights allow businesses to anticipate trends and tailor their software strategies for maximum impact and efficiency. This forward-thinking approach ensures that Forescribe remains at the forefront of the industry, helping clients navigate the complexities of digital asset management with ease and precision.
Specifically designed to meet the distinct needs of operational, IT, and finance teams, Forescribe’s solutions adeptly addresses various organisational demands—from cost optimisation and vendor management to enhancing workflow and ensuring compliance. The platform’s versatility makes it an essential tool for strengthening departmental efficiency and driving substantial cost savings.
For organisations ranging from mid-size businesses to expansive large enterprises in the US, APAC, and EMEA regions, Forescribe offers a comprehensive suite of tools that align with the unique challenges and scales of their operations. Whether it’s scaling up operations effectively or managing extensive software portfolios, Forescribe provides the necessary insights and control to ensure seamless and efficient management.
With its innovative solutions and commitment to operational excellence, Forescribe helps organisations thrive during the digital revolution. This platform is not just a tool but a strategic asset for any forward-thinking enterprise looking to leverage digital capabilities to their fullest potential.
![Net income increases to EUR 443 million due to portfolio measures Initial cost savings generated with “FORWARD!” action plan Mumbai (Maharashtra) [India]: Specialty chemicals company LANXESS had sales in fiscal year 2023 amounted to EUR 6.714 billion, down 17.0 percent from the previous year’s figure of EUR 8.088 billion. EBITDA pre exceptionals decreased by 44.9 percent to EUR 512 million compared with EUR 930 million the year before. The EBITDA margin pre exceptionals reached 7.6 percent, against 11.5 percent the previous year. The weaker demand and the associated reduction in sales volumes as well as higher idle costs led to a significant earnings decline, primarily in the Specialty Additives and Advanced Intermediates segments. In addition, lower procurement prices for raw materials and energy in these two segments influenced selling prices. Earnings in the Consumer Protection segment saw only a comparatively moderate decline. The contribution from the Microbial Control business acquired from IFF at the beginning of July 2022 had a positive effect here. “German chemistry and we at LANXESS have never seen a year of crises like this before. But we are doing all we can to make it through this phase as stably as possible and to be in the best possible position when times improve again. With our “FORWARD!” action plan, we have taken the right steps at an early stage,” says Matthias Zachert, CEO of LANXESS. 2023 was a year of multiple crises for the German chemical industry: Weak demand in numerous customer industries and market regions combined with inventory reduction by customers, high energy prices in Germany, and geopolitical tensions. This also characterized fiscal year 2023 for the specialty chemicals company LANXESS. For the current year, however, the Group expects a moderate increase in earnings. At EUR 443 million, net income in 2023 was significantly higher than the previous year’s figure of EUR 250 million. This was particularly due to the proceeds that LANXESS received from Advent International as a result of the transaction for the formation of Envalior. At minus EUR 843 million, net income from continuing operations was significantly down from the previous year’s figure of EUR 184 million. The decline resulted primarily from the development of operating earnings and impairment on goodwill from acquisitions. LANXESS expects the environment to remain challenging, at least in the first half of 2024. The Group consequently foresees no improvement in the first quarter of 2024 compared with the fourth quarter of 2023 and expects EBITDA pre exceptionals of up to EUR 100 million. Starting in the second quarter, LANXESS anticipates a moderate increase in sales volumes. “We assume that the inventory reduction among our customers is complete, with the exception of the agrochemicals sector. In addition, we expect long-term cost savings from our “FORWARD!” action plan,” says Matthias Zachert. For fiscal year 2024 as a whole, LANXESS expects EBITDA pre exceptionals to be moderately higher than the 2023 figure. “However, earnings will still be significantly below the average level of previous years. In 2024, we will therefore continue to work on our positioning and processes and strengthen our financial base,” says Zachert.](https://republicnewsindia.com/wp-content/uploads/2024/03/LANXESS-CEO-Matthias-Zachert-at-the-annual-press-conference.jpg)
